The U.S. Food and Drug Administration on Wednesday approved a blood cancer treatment from Japan's Astellas Pharma Inc, making it the first targeted therapy to treat patients with a certain mutation.
from Reuters: Health News https://ift.tt/2E1z13z
via
IFTTT